The biosensor has a quantitative readout of G6PD activity and provides a number of advantages over a qualitative RDT, including the possibility to design malaria treatment schemes based on the test readout, the ability to use readouts for drugs outside of 8-aminoquinolines and improved identification of heterozygous females with intermediate G6PD activity. The gene discussed is G6PD; the disease is malaria.